Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3086998
Max Phase: Preclinical
Molecular Formula: C30H55N7O5
Molecular Weight: 593.81
Molecule Type: Small molecule
Associated Items:
ID: ALA3086998
Max Phase: Preclinical
Molecular Formula: C30H55N7O5
Molecular Weight: 593.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCC(=O)N[C@@H](C)/C=C/C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)/C=C/C(=O)N[C@@H](CCCCN)C(N)=O
Standard InChI: InChI=1S/C30H55N7O5/c1-4-5-6-7-8-15-26(38)34-22(2)16-18-28(40)37-25(14-10-12-21-32)30(42)35-23(3)17-19-27(39)36-24(29(33)41)13-9-11-20-31/h16-19,22-25H,4-15,20-21,31-32H2,1-3H3,(H2,33,41)(H,34,38)(H,35,42)(H,36,39)(H,37,40)/b18-16+,19-17+/t22-,23-,24-,25-/m0/s1
Standard InChI Key: ZDBVKOQQWMUGIB-OLJIXPHWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 593.81 | Molecular Weight (Monoisotopic): 593.4265 | AlogP: 1.18 | #Rotatable Bonds: 24 |
Polar Surface Area: 211.53 | Molecular Species: BASE | HBA: 7 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 13.13 | CX Basic pKa: 10.51 | CX LogP: 0.54 | CX LogD: -4.67 |
Aromatic Rings: 0 | Heavy Atoms: 42 | QED Weighted: 0.06 | Np Likeness Score: 0.35 |
1. Shankar SS, Benke SN, Nagendra N, Srivastava PL, Thulasiram HV, Gopi HN.. (2013) Self-assembly to function: design, synthesis, and broad spectrum antimicrobial properties of short hybrid E-vinylogous lipopeptides., 56 (21): [PMID:24117107] [10.1021/jm400884w] |
Source(1):